Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi: 10.1007/s00125-017-4342-z
First developed in the 1980s, MT2 has become a widely referenced compound in peptide research due to its high binding affinity for melanocortin receptors MC1R through MC5R
What they found (summary): Development of Melanotan II as a cutaneous drug failed due to the combination of side effects Bifurcation into more selective derivatives was both scientifically and commercially successful PT-141 Bremelanotide (Vyleesi, 2019) Melanotan I Afamelanotide (Scenesse, 2014) Underground use of Melanotan II is safety-problematic Why it matters: This is the definitive historical review by the founders of the field
AI siRNA Design: Alnylam and Inceptive Deal Analysis Learn how Alnylam and Inceptive use generative AI foundation models for siRNA design, exploring the $2B deal structure and pharma's build-vs-partner strategy
AOD-9604 Pe
US$ 23.59
US$ 28.93
&srotate=0)
US$ 23.50
